Key Highlights

  • InMode (NASDAQ:INMD) rose 3.57% pre-market despite flat sales, with a Market Value of USD 823 million and an RSI of 46.5, on 8,013 shares, on 8,013 shares, on 8,013 shares, on 8,013 shares, on 8,013 shares.
  • Jaguar Health (NASDAQ:JAGX) fell 5.17% pre-market after a rare-disease pivot funded by a license, with a market value of USD 9 million and an RSI of 45.4, on 19,904 shares, on 19,904 shares, on 19,904 shares.
  • Apimeds Pharmaceuticals US (NYSEAMERICAN:APUS) fell 5.19% pre-market after a late filing notice, with a market value of USD 8 million and an RSI of 53.7, on 16,007 shares, on 16,007 shares, on 16,007 shares.
  • Picard Medical (NYSEAMERICAN:PMI) fell 6.08% pre-market after a reverse split, with a market value of USD 27 million and an RSI of 76.2, on 667 shares, on 667 shares, on 667 shares, on 667 shares.

InMode (NASDAQ:INMD): Cash-Rich, Margins Shrinking

InMode (NASDAQ:INMD) rose 3.57% pre-market to a listed USD 14.30 on 8,013 shares, with a market Capitalization of USD 823 million and an RSI of 46.5 labeled Mixed. InMode reported second-quarter 2026 results on August 5, with Revenue of USD 95.6 million, consistent with a year earlier, GAAP operating Margin of 13% versus 24% and non-GAAP Net Income of USD 20.8 million, or USD 0.35 per share. Consumables and service revenue grew 13% to USD 22.3 million, driven mainly by international markets, and Asia produced a quarterly record. Cash and investments totaled USD 537.2 million at March 31, equal to about 65% of the USD 823 million market value, simple arithmetic, and the company had repurchased 2.55 million shares for USD 34.8 million. A CFO transition was announced in the first quarter, and Steel Partners, an activist investor, sent a letter around the July annual meeting. GAAP Earnings per diluted share fell to USD 0.29 from USD 0.42, so profit is shrinking even though the Balance Sheet is strong. Margin erosion, flat sales and activist pressure leave the story unsettled despite the cash. By market value it ranks 1 of 4 in this group. What to watch next: the next quarterly results, margin trends and the activist campaign.

Jaguar Health (NASDAQ:JAGX): Pipeline Pivot to Rare Disease

Jaguar Health (NASDAQ:JAGX) fell 5.17% pre-market to a listed USD 4.64 on 19,904 shares, with a market capitalization of USD 9 million and an RSI of 45.4 labeled Down. Jaguar Health received USD 16 million of non-dilutive cash in January 2026 under a royalty-free US license of Mytesi and Canalevia-CA1 to Future Pak, which directs those US revenues away from Jaguar. The company is now concentrating on crofelemer for rare intestinal failure diseases, including microvillus inclusion disease, with a presentation at ESPGHAN 2026 describing parenteral support reductions in pediatric patients. First-quarter net revenue rose 816% from a year earlier on the license, and Research and Development expense was USD 3.9 million in the quarter. The company expects the NDA clinical package for MVID by year-end and plans an NDA filing in the second quarter of 2027, and the license includes up to USD 20 million of milestones and other payments, with USD 3.0 million already received. The USD 9 million market value is about half of the USD 16 million upfront payment, simple arithmetic, which shows how little the market credits the pipeline. Revenue is small, funding needs are recurring and a Nasdaq listing risk was flagged in its annual filing, so dilution is likely. By market value it ranks 3 of 4 in this group. What to watch next: the MVID NDA package, Future Pak milestones and financing.

Apimeds Pharmaceuticals US (NYSEAMERICAN:APUS): Late 10-K, Second Phase 3

Apimeds Pharmaceuticals US (NYSEAMERICAN:APUS) fell 5.19% pre-market to a listed USD 5.20 on 16,007 shares, with a market capitalization of USD 8 million and an RSI of 53.7 labeled Up. Apimeds Pharmaceuticals US is a clinical-stage company developing Apitox, a bee venom-based toxin given intradermally, which has been used in South Korea to treat osteoarthritis pain since 2003. It plans a second Phase 3 trial to meet FDA standards and intends to submit a BLA only after demonstrating therapeutic effect and extended safety. The notice added a late-filing designation to the ticker, and a Trading halt that began on April 2, 2026 remained in effect when the notice was filed. A September 29 current report concerned MindWave, a wholly owned subsidiary, and the six-month cure period for the 10-K runs to about October 17. The USD 8 million market value means the company needs outside capital to fund a Phase 3 trial. A looming cure deadline, delisting risk, a costly second Phase 3 trial and a tiny market value make dilution very likely. By market value it ranks 4 of 4 in this group. What to watch next: the 10-K filing, the exchange cure deadline and Phase 3 funding.

Picard Medical (NYSEAMERICAN:PMI): Revenue Up 39%, Reverse Split

Picard Medical (NYSEAMERICAN:PMI) fell 6.08% pre-market to a listed USD 11.34 on 667 shares, with a market capitalization of USD 27 million and an RSI of 76.2 labeled Up, overbought. Picard Medical is the parent of SynCardia Systems, maker of the SynCardia Total Artificial Heart, which is approved by both the FDA and Health Canada and is the only commercially available total artificial heart in the United States and Canada. The company reported second-quarter 2026 results on August 19, with revenue up 39% to about USD 3.0 million on higher US sales of about USD 0.8 million and a net loss that narrowed 16% to about USD 5.7 million. Picard completed a 1-for-50 Reverse Stock Split on July 31, 2026, following stockholder approval, to support compliance with NYSE American standards, and it responded earlier in 2026 to a continued listing notice. In May 2026 it priced a USD 5 million offering of 16,666,667 shares plus warrants exercisable at USD 0.35 before the split, and its September 2025 IPO raised USD 19.6 million at USD 4.00 a share. Full-year 2025 revenue was USD 4.9 million, up 12.5%, with a negative 4.1% gross margin and year-end cash of USD 11.5 million after USD 15.7 million of operating cash burn. A USD 27 million market value, negative gross margin, recurring Equity raises and a post-split price that can swing on 667 shares make the stock highly volatile. By market value it ranks 2 of 4 in this group. What to watch next: the Emperor heart program, quarterly gross margin and financing.

Where Things Stand

Small healthcare movers had no same-day company news, but filings show a rare-disease pivot, a late 10-K and flat device sales, on volumes of 667 to 19,904 shares. InMode (NASDAQ:INMD) rose 3.57% with a market value of USD 823 million. Jaguar Health (NASDAQ:JAGX) fell 5.17% with a market value of USD 9 million. Apimeds Pharmaceuticals US (NYSEAMERICAN:APUS) fell 5.19% with a market value of USD 8 million. Picard Medical (NYSEAMERICAN:PMI) fell 6.08% with a market value of USD 27 million. Pre-market moves on thin Volume often reverse, so the balance of evidence favors waiting for the open and for filings. Direction remains unknown, and each name carries its own risks. Verify the latest filings before acting, and treat the figures as a snapshot.